Treatment of Opioid Use Disorder Among Commercially Insured Patients in the Context of the COVID-19 Pandemic

Treatment of Opioid Use Disorder Among Commercially Insured Patients in the Context of the COVID-19 Pandemic

This study uses commercial and Medicare Advantage claims data to compare medication fills, outpatient visits, and urine tests for opioid use disorder in January-May 2020 vs 2019.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JAMA : the journal of the American Medical Association 2020-12, Vol.324 (23), p.2440-2442
Hauptverfasser: Huskamp, Haiden A, Busch, Alisa B, Uscher-Pines, Lori, Barnett, Michael L, Riedel, Lauren, Mehrotra, Ateev
Format: Artikel
Sprache:eng
Schlagworte:
Adolescent
Adult
Buprenorphine - therapeutic use
COVID-19
Drug addiction
Drug Prescriptions - statistics & numerical data
Drug Utilization - trends
Female
Government programs
Humans
Insurance Coverage
Letter
Letters
Male
Medicare
Middle Aged
Narcotic Antagonists - therapeutic use
Narcotics
Opioid-Related Disorders - drug therapy
Opioids
Pandemics
Research Letter
Substance use disorder
United States
Young Adult
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:This study uses commercial and Medicare Advantage claims data to compare medication fills, outpatient visits, and urine tests for opioid use disorder in January-May 2020 vs 2019.
ISSN:0098-7484
1538-3598
DOI:10.1001/jama.2020.21512